1887
Research Open Access
Like 0

Abstract

Introduction

Estimating burden of disease (BoD) is an essential first step in the decision-making process on introducing new vaccines into national immunisation programmes (NIPs). For varicella, a common vaccine-preventable disease, BoD in the Netherlands was unknown.

Aim

To assess national varicella BoD and compare it to BoD of other vaccine-preventable diseases before their introduction in the NIP.

Methods

In this health estimates reporting study, BoD was expressed in disability-adjusted life years (DALYs) using methodology from the Burden of Communicable Diseases in Europe (BCoDE)-project. As no parameters/disease model for varicella (including herpes zoster) were available in the BCoDE toolkit, incidence, disease progression model and parameters were derived from seroprevalence, healthcare registries and published data. For most other diseases, BoD was estimated with existing BCoDE-parameters, adapted to the Netherlands if needed.

Results

In 2017, the estimated BoD of varicella in the Netherlands was 1,800 (95% uncertainty interval (UI): 1,800–1,900) DALYs. Herpes zoster mainly contributed to this BoD (1,600 DALYs; 91%), which was generally lower than the BoD of most current NIP diseases in the year before their introduction into the NIP. However, BoD for varicella was higher than for rotavirus gastroenteritis (1,100; 95%UI: 440–2,200 DALYs) and meningococcal B disease (620; 95%UI: 490–770 DALYs), two other potential NIP candidates.

Conclusions

When considering the introduction of a new vaccine in the NIP, BoD is usually estimated in isolation. The current approach assesses BoD in relation to other vaccine-preventable diseases’ BoD, which may help national advisory committees on immunisation and policymakers to set vaccination priorities.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.18.1800363
2019-05-02
2019-12-14
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.18.1800363
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/18/eurosurv-24-18-3.html?itemId=/content/10.2807/1560-7917.ES.2019.24.18.1800363&mimeType=html&fmt=ahah

References

  1. Spoulou V, Alain S, Gabutti G, Giaquinto C, Liese J, Martinon-Torres F, et al. Implementing Universal Varicella Vaccination in Europe: The Path Forward. Pediatr Infect Dis J. 2019;38(2):181-8.  https://doi.org/10.1097/INF.0000000000002233  PMID: 30408002 
  2. European Centre for Disease Prevention and Control (ECDC). Immunisation schedules. Stockholm: ECDC; 2019. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
  3. Houweling H, Verweij M, Ruitenberg EJNational Immunisation Programme Review Committee of the Health Council of the Netherlands. Criteria for inclusion of vaccinations in public programmes. Vaccine. 2010;28(17):2924-31.  https://doi.org/10.1016/j.vaccine.2010.02.021  PMID: 20189486 
  4. Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365-76.  https://doi.org/10.1016/S0140-6736(06)69561-5  PMID: 17046469 
  5. van Lier A, Smits G, Mollema L, Waaijenborg S, Berbers G, van der Klis F, et al. Varicella zoster virus infection occurs at a relatively young age in The Netherlands. Vaccine. 2013;31(44):5127-33.  https://doi.org/10.1016/j.vaccine.2013.08.029  PMID: 23973248 
  6. Colzani E, Cassini A, Lewandowski D, Mangen MJ, Plass D, McDonald SA, et al. A Software Tool for Estimation of Burden of Infectious Diseases in Europe Using Incidence-Based Disability Adjusted Life Years. PLoS One. 2017;12(1):e0170662.  https://doi.org/10.1371/journal.pone.0170662  PMID: 28107447 
  7. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448-57.  https://doi.org/10.1056/NEJMra1201534  PMID: 23902484 
  8. Mangen MJ, Plass D, Havelaar AH, Gibbons CL, Cassini A, Mühlberger N, et al. BCoDE consortium. The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseases. PLoS One. 2013;8(11):e79740.  https://doi.org/10.1371/journal.pone.0079740  PMID: 24278167 
  9. Bijkerk P, van Lier A, McDonald S, Kardamanidis K, Fanoy EB, Wallinga J, et al. State of infectious diseases in the Netherlands, 2013. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2014 (RIVM report 150205001). Available from: http://www.rivm.nl/bibliotheek/rapporten/150205001.pdf
  10. van Lier A, McDonald SA, Bouwknegt M, Kretzschmar ME, Havelaar AH, Mangen MJ, et al. EPI group. Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011. PLoS One. 2016;11(4):e0153106.  https://doi.org/10.1371/journal.pone.0153106  PMID: 27097024 
  11. Havelaar AH, Haagsma JA, Mangen MJ, Kemmeren JM, Verhoef LP, Vijgen SM, et al. Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol. 2012;156(3):231-8.  https://doi.org/10.1016/j.ijfoodmicro.2012.03.029  PMID: 22541392 
  12. van Lier A, Lugnér A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, et al. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster. EBioMedicine. 2015;2(10):1494-9.  https://doi.org/10.1016/j.ebiom.2015.08.017  PMID: 26629544 
  13. Schurink-van ’t Klooster TM, de Melker HE. The National Immunisation Programme in the Netherlands – Surveillance and developments in 2016-2017. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2017 (RIVM report 2017-0143). Available from: http://www.rivm.nl/bibliotheek/rapporten/2017-0143.pdf
  14. Dutch Hospital Data. National Medical Register (LMR). Utrecht: Dutch Hospital Data; 2000-2014.
  15. Statistics Netherlands. Deaths by main primary cause of death, sex and age. Voorburg: CBS; 2000-2016.
  16. Kristensen M, van Lier A, Eilers R, McDonald SA, Opstelten W, van der Maas N, et al. Burden of four vaccine preventable diseases in older adults. Vaccine. 2016;34(7):942-9.  https://doi.org/10.1016/j.vaccine.2015.12.052  PMID: 26752065 
  17. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-43.  https://doi.org/10.1016/S0140-6736(12)61680-8  PMID: 23245605 
  18. Kwong JC, Crowcroft NS, Campitelli MA, Ratnasingham S, Daneman N, Deeks SL, et al. Ontario Burden of Infectious Disease Study (ONBOIDS): An OAHPP/ICES Report. Toronto: Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences; 2010.
  19. World Health Organization (WHO). WHO methods and data sources for global burden of disease estimates 2000-2011. Geneva: WHO; 2013 (Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2013.4). Available from: http://www.who.int/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf
  20. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control. 2017;28(3):203-14.  https://doi.org/10.1007/s10552-017-0870-6  PMID: 28213874 
  21. Department of Human Services (DHS). The Victorian burden of disease study: mortality and morbidity in 2001. Melbourne: DHS; 2005. Available from: http://ausvegvic.com.au/pdf/2001%20Victorian%20Burden%20of%20Disease%20Report_summary.pdf
  22. Haagsma JA, Maertens de Noordhout C, Polinder S, Vos T, Havelaar AH, Cassini A, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13(1):10.  https://doi.org/10.1186/s12963-015-0042-4  PMID: 26778920 
  23. Roper MH, Wassilak SGF, Scobie HM, Ridpath AD, Orenstein WA. Tetanus Toxoid. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines (7th edition). Philadelphia: Elsevier; 2018. p. 1052-79.
  24. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.  https://doi.org/10.1016/S1470-2045(10)70230-8  PMID: 20952254 
  25. Statistics Netherlands. Life expectancy; sex, age (per year and period of 5 years). Voorburg: CBS; 2017; Available from: http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37360ned&D1=3&D2=0&D3=a&D4=20-21,25,45,49,61,68,79,83,89,l&HDR=G1,T,G3&STB=G2&VW=T
  26. van Wijhe M, McDonald SA, de Melker HE, Postma MJ, Wallinga J. Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. Lancet Infect Dis. 2016;16(5):592-8.  https://doi.org/10.1016/S1473-3099(16)00027-X  PMID: 26873665 
  27. van Wijhe M, Tulen AD, Korthals Altes H, McDonald SA, de Melker HE, Postma MJ, et al. Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands. Epidemiol Infect. 2018;146(6):716-22.  https://doi.org/10.1017/S0950268818000481  PMID: 29534768 
  28. Colzani E, McDonald SA, Carrillo-Santisteve P, Busana MC, Lopalco P, Cassini A. Impact of measles national vaccination coverage on burden of measles across 29 Member States of the European Union and European Economic Area, 2006-2011. Vaccine. 2014;32(16):1814-9.  https://doi.org/10.1016/j.vaccine.2014.01.094  PMID: 24530930 
  29. van Lier A, Ferreira JA, Mollema L, Sanders EAM, de Melker HE. Intention to vaccinate universally against varicella, rotavirus gastroenteritis, meningococcal B disease and seasonal influenza among parents in the Netherlands: an internet survey. BMC Res Notes. 2017;10(1):672.  https://doi.org/10.1186/s13104-017-3004-z  PMID: 29202798 
  30. van Lier A, van der Maas NA, Rodenburg GD, Sanders EA, de Melker HE. Hospitalization due to varicella in the Netherlands. BMC Infect Dis. 2011;11(1):85.  https://doi.org/10.1186/1471-2334-11-85  PMID: 21466668 
  31. van Lier A, van Erp J, Donker GA, van der Maas NA, Sturkenboom MC, de Melker HE. Low varicella-related consultation rate in the Netherlands in primary care data. Vaccine. 2014;32(28):3517-24.  https://doi.org/10.1016/j.vaccine.2014.04.034  PMID: 24791730 
  32. van de Bovenkamp-Meijer KJT, Rümke HC. Twijfels over kindervaccinaties: betere voorlichting zal het draagvlak versterken. [Doubts about childhood vaccinations: improved information will enhance public support]. Med Contact (Bussum). 2005;60(1):18-21. Dutch.
  33. Harmsen IA. Vaccinating: self-evident or not?: development of a monitoring system to evaluate acceptance of the national immunization program. Maastricht: Maastricht University; 2014. Available from: https://cris.maastrichtuniversity.nl/portal/en/publications/vaccinating--selfevident-or-not--development-of-a-monitoring-system-to-evaluate-acceptance-of-the-national-immunization-program(797078f9-3379-4484-9484-8400420e8d9a)/export.html
  34. van Lier A, Tostmann A, Harmsen IA, de Melker HE, Hautvast JL, Ruijs WL. Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys. BMC Infect Dis. 2016;16(1):127.  https://doi.org/10.1186/s12879-016-1442-1  PMID: 26979822 
  35. Veldwijk J, Lambooij MS, Bruijning-Verhagen PC, Smit HA, de Wit GA. Parental preferences for rotavirus vaccination in young children: a discrete choice experiment. Vaccine. 2014;32(47):6277-83.  https://doi.org/10.1016/j.vaccine.2014.09.004  PMID: 25236585 
  36. Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. J Infect Dis. 2013;208(11):1859-68.  https://doi.org/10.1093/infdis/jit405  PMID: 23922376 
  37. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.  https://doi.org/10.1056/NEJMoa051016  PMID: 15930418 
  38. van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10(1):237.  https://doi.org/10.1186/1472-6963-10-237  PMID: 20707884 
  39. de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276-83.  https://doi.org/10.1016/j.vaccine.2012.12.067  PMID: 23306360 
  40. de Boer PT, van Lier A, de Melker H, van Wijck AJM, Wilschut JC, van Hoek AJ, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228.  https://doi.org/10.1186/s12916-018-1213-5  PMID: 30518427 
  41. Health Council of the Netherlands. Algemene vaccinatie tegen hepatitis B herbeoordeeld. [General vaccination against hepatitis B revisited]. The Hague: Health Council of the Netherlands; 2009. publication no. 2009/03. Dutch.
  42. Knol MJ, Ruijs WLM, Antonise-Kamp L, de Melker HE, van der Ende A. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill. 2018;23(16):1800158.  https://doi.org/10.2807/1560-7917.ES.2018.23.16.18-00158  PMID: 29692317 
  43. Health Council of the Netherlands. Advies inzake bof/rubellavaccinatie. [Advice on mumps/rubella vaccination]. The Hague: Staatsuitgeverij; 1984. Dutch.
  44. Health Council of the Netherlands. De toekomst van het Rijksvaccinatieprogramma: naar een programma voor alle leeftijden. [The future of the national immunisation programme: towards a programme for all age groups]. The Hague: Health Council of the Netherlands; 2007. publication no. 2007/02. Dutch.
  45. Health Council of the Netherlands. Vaccinatie tegen rotavirus. [Vaccination against rotavirus]. The Hague: Health Council of the Netherlands; 2017. publication no. 2017/16. Dutch.
  46. Bruijning-Verhagen P, van Dongen JAP, Verberk JDM, Pijnacker R, van Gaalen RD, Klinkenberg D, et al. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting. BMC Med. 2018;16(1):168.  https://doi.org/10.1186/s12916-018-1134-3  PMID: 30196794 
  47. Mackenbach JP. De epidemiologische transitie in Nederland. [The epidemiological transition in The Netherlands]. Ned Tijdschr Geneeskd. 1993;137(3):132-8. PMID: 8423862 
  48. van den Hof S, Conyn-van Spaendonck MAE, de Melker HE, Geubbels ELPE, Suijkerbuijk AWM, Talsma E, et al. The effects of vaccination, the incidence of the target diseases. Bilthoven: National Institute for Public Health and the Environment (RIVM); 1998 (RIVM report 213676008). Available from: http://www.rivm.nl/bibliotheek/rapporten/213676008.pdf
  49. Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, et al. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. J Infect Dis. 2018;217(2):213-22.  https://doi.org/10.1093/infdis/jix582  PMID: 29140439 
  50. Hoogendoorn D. De inentingen tegen diphtherie en de propaganda hiervoor. [Vaccination against diphtheria and propaganda to this end]. Ned Tijdschr Geneeskd. 1954;98(26):1806-9. Dutch. PMID:13185342 PMID: 13185342 
  51. van der Maas NAT, Hoes J, Sanders EAM, de Melker HE. Severe underestimation of pertussis related hospitalizations and deaths in the Netherlands: A capture-recapture analysis. Vaccine. 2017;35(33):4162-6.  https://doi.org/10.1016/j.vaccine.2017.06.037  PMID: 28651837 
  52. Bol P. Epidemiologie van Haemophilus influenzae type b-infecties in Nederland en elders. [Epidemiology of Haemophilus influenzae type b infections in The Netherlands and elsewhere]. Ned Tijdschr Geneeskd. 1991;135(1):7-9. Dutch. PMID: 1990304 
/content/10.2807/1560-7917.ES.2019.24.18.1800363
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error